Tags Posts tagged with "Marijuana Industry News"

Marijuana Industry News

0 1075

Lawmakers are proposing to legalize recreational cannabis in Illinois, however the legislation will most likely not come up for a vote until 2018. Advocates recently introduced proposals that would make it legal for adults 21 and older to grow, buy, and possess limited amounts of cannabis.

Sponsors said the state would license and regulate businesses to grow, process, and sell the plant, and it would establish safety regulations such as testing and labeling requirements. The proposal would also allow residents to possess up to 28 grams of marijuana and to grow five plants. The bills propose taxing cannabis at a rate of $50 per ounce wholesale, plus the state’s standard 6.25% sales tax.

Based on sales of recreational cannabis in Colorado, the Marijuana Policy Project, a national advocacy group, estimates sales in Illinois could generate about $350 million to $700 million per year. Governor Bruce Rauner and House Speaker Michael Madigan reserved judgment, as they typically do with new proposals. However, the Illinois Association of Chiefs of Police opposes legalization, saying cannabis poses a threat to public health and safety, and causes potential enforcement problems because it conflicts with the federal restriction on cannabis.

The co-sponsors, Senator Heather Steans and Representative Kelly Cassidy, both Democrats from Chicago’s North Side, said they do not plan to call the proposal for a vote this session but will hold hearings to get feedback and see whether some version of a legalization proposal can get support next year. Steans said, “If we bring this out in the open, we can generate revenue legally rather than for the black market.”

Cassidy said cannabis prohibition creates far more problems than it prevents. She said, “Regulating marijuana and removing the criminal element from marijuana production and sales will make our communities safer.” Eight states have permitted the sale of the drug, generally by referendum. However, in Illinois, it’s very challenging to get a binding vote on the statewide ballot, so it probably would take legislative action to change the law.

0 819

Recently, Legislature sent separate proposals to the floor pushing for the legalization of commercial hemp production in West Virginia. Often, hemp is associated with marijuana. However, the new legislation declares hemp’s industrial uses. The bills state as long as the crop stays below a 1% threshold of tetrahydrocannabinol, the psychoactive component of cannabis, it can be produced after receiving licensing from the Agriculture Commissioner.

At its meeting Wednesday, the Senate Agriculture Committee sent Senate Resolution 35 up to the chamber floor. That resolution, if passed through the House of Delegates as well, works as a call from the Legislature to the U.S. Congress to distinguish hemp from marijuana by the THC threshold. Senator Robert Beach said commercial hemp means jobs for West Virginia in terms of production, manufacturing it into commercial products, and retail.

As far as its special proximity to cannabis, he said the two crops’ usages show their differences.
He said, “With hemp, the old saying is you could smoke 500 acres of it and it won’t get you high.” According to the resolution, hemp products can be made through the crop’s fiber, seed, seed oil, and floral extracts including paper, fabric, body care products, and essential oils, according to the resolution.

Senator Sue Cline voiced support for the resolution as well. She said Kentucky already has embraced hemp as a cash crop, and it’s time for West Virginia to catch up. Communications director for the West Virginia Department of Agriculture, Crescent Gallagher, said the department fully supports both the Senate resolution and the House proposal. Though the crop’s relationship to cannabis has gummed up similar legislation in the past, he said newfound support could push the proposal through this year.

He said, “The Department fully supports the Senate resolution and House bill. We believe hemp is a niche crop that has the opportunity to bring producers into the state.” Only the Department of Agriculture and colleges and universities authorized by the Agriculture Commissioner can grow hemp in the state under current law.

Following suit with the Senate, the House Judiciary Committee chose to send HB 24 53 to the floor, which gives discretion to the Commissioner of Agriculture to dispense licenses to produce hemp commercially. However, it only allows those licensed through a university to grow hemp for research purposes, not commercial ones.

0 1081

HempLife Today to Premiere New 24 Hour Interactive Customer Support Phone System Developed to Improve Customer Support, Customer Satisfaction, and Increase Sales Volume

This new IVR system was developed using one of the most technologically advanced software applications in the industry, and will help the Company to better serve its daily increase of customers for its growing line of CannazALL™ CBD products derived from Hemp, by offering an easier way to learn more about the Company, the products, and to better speak to a specialist who can assist in taking an order.

This system will offer hundreds, and thousands, of daily customers the ability to access information about CannazALL™ CBD products, dosing, CBD uses, and other important information, as well as speaking to a highly trained CBD expert employed exclusively by HempLife Today™.

The new IVR phone will be fully interactive and customers will have the ability to learn about the following topics 24 hours a day:

Press 1 at any time to speak to a representative
Press 2 to learn more about HempLife Today
Press 3 to learn more about CBD
Press 4 to learn more about CannazALL CBD products and dosing
Press 5 to learn more about our shipping process and quality pledge
Press 6 to learn more about our Rebate and Referral programs
Press 7 to learn more about our money-back guarantee
Press 8 for Investment information

The Company chose both a male and female nationally known professional voice over talent to host the system, creating a more youthful, energetic, fun and friendly experience for the caller.

“With our new IVR system our customers will have all of the necessary information about our company and products at their fingertips 24 hours a day,” said Luke Dreyer, head of operations. “This will take pressure off of our live representatives and give them more time to spend with each customer, creating a better customer satisfaction and sales opportunity.”

“With the volume of customers we are currently getting, and the volume we are going to increase to, it was time for us to create this new phone system,” adds James Ballas, CEO. “Customer service is the cornerstone of our success, along with our superior products, and we want our customers to have a number they can call 24 hours a day to get the information they need so that we are always serving our customers’ needs. This is just one more area where we continue to excel, and this new system will increase our sales and add to our bottom line.”

The Company plans to have this new IVR system in place by Friday March 31st no later than 5pm Eastern, and shareholders and customers can access through the main number on the HempLife Today™ Website at 1.800.655.9547

About Ubiquitech (HempLife Today™)

Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLife Today™.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; Its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 787

VPR Brands will be participating in CannaGrow Expo, March 25-26th in Reno, Nevada

“Our company is continuing to network at every major industry event in the cannabis space and this event in particular will attract our customer base interested in private labeling our oil tanks which work best to vaporize their cannabis oil extracts. The event attendance and interest level reflects the growth in the industry. These targeted and more intimate industry events are the best way to get to know your customers and for them to get to know you. Leading to stronger long term relationships that will continue to grow as the industry grows,”‎ says Kevin Frija, CEO of VPR Brands, LP.

“The market is very bullish on Nevada’s growth potential within the cannabis space, so I think this is a great show for us to market our products and our latest technology. I will personally attend and support the team and have an opportunity to meet with potential and existing clients,” says Dan Hoff, COO of VPR Brands, LP.

About CannaGrow:
The CannaGrow Expo features an expo hall full of great brands with a very singular focus around creating the most successful cannabis grows and extractions in the world. There is no better place to find the education, products, and services to grow premium cannabis than the CannaGrow Expo. Current growers grow managers, dispensary owners, and those just interested in learning about cultivating cannabis are encouraged to attend.

About VPR Brands LP:
VPR Brands is a technology company, whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the company on the web at www.vprbrands.com.

Forward-looking statements:
This news release contains statements that involve expectations, plans or intentions, and other factors discussed from time to time in the company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. The company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

0 3505

Today was a busy day for cannabis stocks and this is important as it follows a couple rough weeks of trading.

Some of the important develops we think investors should take note of, include:

1. MassRoots, Inc. (MSRT) announced that Google Play approved its mobile application for distribution to Android devices. In early November, MassRoots was removed from Google Play due to a compliance review.
2. Emblem Corp (EMC.V) (EMMBF) had its Speculative Buy rating and $3.75 price target reaffirmed by Canaccord Genuity. The report said:
3. CanniMed Therapeutics (CMED.TO: TSX) announced the receipt of its first two Health Canada issued export permits for medical cannabis oils. In addition, CanniMed received initial purchase orders for all three CanniMed Oils for distribution to both Australia and the Cayman Islands for pharmacy dispensing. These two Health Canada-issued export permits will include all three oil products. By June 30th, CanniMed will have shipped 3,600 ml and 12,960 ml of CanniMed Oils to Australia and the Cayman Islands respectively. The company expects to provide additional details with respect to these developing opportunities within the coming weeks.
4. Golden Leaf Holdings Ltd. (GLDFF) signed a binding Letter of Agreement to acquire Chalice, a vertically integrated Oregon based cannabis company. In conjunction with the transaction, Golden Leaf entered into an engagement agreement with Canaccord Genuity with respect to a best efforts brokered private placement. The company plans to sell approx. $35 million worth of subscription receipts and the net proceeds will be used to satisfy the cash component of the purchase price for the Chalice Farms and to fund the company.
5. Future Farm Technologies’ (FFRMF) (FFT.CN) majority owned subsidiary, FFM Consulting Services purchased an extraction machine for the manufacture of concentrated cannabis oil and purified distillate. The equipment is estimated to be delivered, installed and in full production within the next 90 days.
6. American Cannabis (AMMJ) announced that five of its active clients have successfully submitted applications for acquiring business licenses to operate within Pennsylvania’s medical cannabis program. Two clients have applied for licenses to legally dispense, one applied for a license to legally cultivate, and two clients have applied to do both.
7. NEMUS Bioscience, Inc. (NMUS) and the University of Mississippi announced that bactericidal synergy was achieved against multiple species of MRSA utilizing a proprietary cannabinoid-based therapeutic platform.

Pursuant to an agreement between MAPH and Future Farm Inc., we were hired for a period of 30 days to publicly disseminate information about (FFRMF) including on the Website and other media including Facebook and Twitter. We are being paid $37,500 (CASH) for and were paid 1 million shares of restricted common shares. We may buy or sell additional shares of (FFRMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. An affiliate of MAPH Enterprises LLC owns 43,500 shares of EMBLEM as well as 21,750 Warrants


0 950
Florida Marijuana

A proposal that would award $2.5 million for UF to study medical marijuana recently moved forward in the Florida House of Representatives. The proposal states that money from the General Revenue Fund will be used to fund UF’s study on the safety and efficiency of medical cannabis. The bill, which passed through the Health Care Appropriations Subcommittee, moved into the Appropriations Committee on Friday.

If the bill is passed in the committee, it will go to a full House vote for final approval. If it passes through the House, the proposal states the one time fund will be finalized in July. House member Dane Eagle, a republican who represents District 77, sponsored the proposal, which was first submitted February 7. Janine Sikes, spokesperson for UF, wrote in an email that the money would fund UF’s proposed Cannabis and Safety Outcomes Surveillance System, a program which would monitor the safety and effectiveness of medical cannabis on 25,000 enrolled patients throughout the state.

Florida’s Amendment 2, a constitutional amendment that allows stronger cannabis to be used for a broader list of conditions, took effect in January. Of the six medical cannabis dispensaries licensed in Florida, two are in Alachua County, according to the Florida Department of Health’s Office of Compassionate Use. Sikes said the UF program would monitor treatments that haven’t been approved by the FDA. UF would create a secure Data Warehouse to track patient data as part of the program.

She said the $2.5 million would be for costs such as faculty salaries and data processing. She stated, “Evidence is lacking to evaluate risk/benefit of medical marijuana. It is pivotal that the state establishes a system to monitor emerging safety concerns, especially for use in children.” She said the proposal is related to the Compassionate Medical Cannabis Act of 2014, which requires physicians to submit a quarterly patient treatment plan to the UF’s College of Pharmacy for research on the safety and effectiveness of low-THC cannabis on patients. The details of the proposal state that it would offer funding to implement research provisions in the 2014 act.

A UF nursing senior, Alicia Ciliezar, said she supports the use and research of medical cannabis. The substance helps improve pain levels for individuals with issues such as neurologic conditions and digestive disorders. She said, “I’m very eager to see the aims of the study, the objectives and the outcomes. I’m sure it will be fascinating and shape our perception on the substance.”

0 952

Although the benefits associated with hemp are endless, researchers have been unable to learn all the benefits associated with it. While significant progress has been made over the last few years, we still have a lot to learn.

This lack of knowledge is not the result of inadequate technology or resources. It is the result of inadequate government policy. Growing hemp has been illegal for almost a century which prevented researchers from being able to learn about the benefits associated with it.

The Next Trillion-Dollar Industry

In 1916 the chief scientists at the Department of Agriculture, created paper from the inner portion of the hemp stem. The paper was said to be better than paper made from pulp wood however, these findings were never confirmed due to the misconception that hemp could get you high.

Industrial hemp and marijuana are two completely different plants, inside and out. Hemp contains a very small amount (less than 1%) of tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana (the chemical that gets a user high).

In 1938, when Popular Mechanics said hemp was a billion-dollar product, they did not even know 20% of the uses associated with hemp. While it is impossible to quantify the newly discovered benefits of hemp, it is possible to determine that $1 billion in 1938 is a much a larger sum of money today.

An Industrial Hemp Revolution

The cannabis industry continues to be the fastest growing industry in the world and many companies working to capitalize on opportunities within this emerging market.

Several products which are used by people every day can be created from hemp. These include paper, clothing, building materials, fuel, and nutrition. Despite industrial hemp’s known benefits, the Federal government has continued to push back on what may one day be a $1 trillion industry.

Hemp Inc. (HEMP) is a company levered to the industrial hemp industry that we have been watching closely. The company was the first business to register with the North Carolina’s hemp commission as a hemp processor and a farm aggregator.

Hemp currently has contracts with 32 farmers and has the first hemp food processing plant that been permitted in North Carolina. The plant is under construction and is expected to start being able to process hemp seed into food later this year (expected to process CBD as well).

A Premier Cultivator and Educator

Not only is Hemp poised to be one of the largest industrial hemp producers in the world, it will also be one of the largest educators.

On Saturday, the company produced the first Hemp University educational symposium. The seminar provided important information and insight when it comes to the history and future of the hemp industry. It also helped teach farmers how to grow, sell and profit from industrial hemp through real world examples.

The seminar featured world renown industry experts from all over the country. From New York to Oregon, from Virginia to Nevada, attendees received in-depth insight and education from several industry leaders.

What is The Hemp University?

The Hemp University was established with the goal to educate its attendees on key topics such as transitioning from traditional farming to organic farming, different hemp cultivar strains, how and where to get certified seeds, planting and harvesting industrial hemp, an in-depth history of hemp and its many uses, agronomy, permaculture, ecological advantages and many more courses as the curriculum is expanded.

Monthly classes will also cover such topics as organic certification, potential licensing fees, what’s happening with industrial hemp in different states around America, high CBD strains and different CBD extraction technologies and marketability of the crop.

Hemp products will continue to be showcased these seminars and anyone interested in attending or speaking at future events should visit www.thehempuniversity.com

MAPH owns “6 million” shares of restricted common shares of Hemp, Inc.  PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 606

DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

Insys Therapeutics, Inc. (INSY) (“Insys” or the “Company”) today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.

On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.

Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively.”

“We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017,” concluded Vetticaden.

Important Safety Information

Syndros is a cannabinoid indicated in adults for the treatment of:

  • Anorexia associated with weight loss in patients with AIDS, and
  • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

The use of dronabinol may cause psychiatric and cognitive effects and impair mental and/or physical abilities.
Patients with cardiac disorders may experience hypotension, hypertension, syncope or tachycardia.
May cause disulfiram-like reaction.
Weigh the potential risk versus benefits before prescribing Syndros to patients with a history of seizures, including those requiring anti-epileptic medication or other factors that lower the seizure threshold.
Assess risk for abuse or misuse in patients with a history of substance abuse or dependence, prior to prescribing Syndros and monitor for the development of associated behaviors or conditions.
Consider dose reduction or discontinuation, if worsening of symptoms while on treatment.
The safety and effectiveness of Syndros have not been established in pediatric patients.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.

SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding (i) the anticipated scheduling and launch of SYNDROS™, (ii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iii) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law.

0 1334
cannabis biotech

$FFRMF Acquires High Volume, State-of-the-Art Cannabis Oil Extraction Equipment


Future Farm Technologies Inc. (the “Company” or “Future Farm”) (FFRMF) (FFT.CN) is pleased to announce that its majority owned subsidiary, FFM Consulting Services, LLC, has purchased a state-of-the-art extraction machine, for the manufacture of concentrated cannabis oil and purified distillate.

The equipment purchased is designed to rapidly manufacture premium cannabis oil, to supply the growing demand for cannabis concentrates, in the state of California. The equipment utilizes a closed-loop system, to produce high quality oil in a high throughput system with minimal maintenance and labor. The equipment is estimated to be delivered, installed and in full production within the next 90 days.


Click Here Now To Read Full PR


San Francisco May Form Cannabis Commission And Cannabis Department


Supervisor Jeff Sheehy, who Mayor Ed Lee appointed to the District 8 post in January, introduced legislation last week that would create a seven-member Cannabis Commission and Cannabis Department with a director and staff in San Francisco. The commission will decide whether to grant or deny permits related to commercial cannabis businesses as well as decide whether to suspend such permits based on yet-to-be-developed guidelines. San Francisco is currently working on regulations for the recreational cannabis industry after California voters legalized the substance by passing Proposition 64 back in November.

Click Here Now To Read Full Article


Marijuana Stocks Especially Cannabis-Biotechs are Capturing Wall Street’s Attention in a Big Way

Marijuana Stocks, especially Cannabis Companies with strong ties to Biotech have been increasingly front and center on Wall Street’s main stage. Marijuana Stocks and the Cannabis-Biotech sector continue to evolve and grow into the mainstream powerhouse we know it can and will be. We have identified a small Cannabis-Biotech start up that deserves your attention.

Click Here Now To Read Full Article


Pursuant to an agreement between MAPH and Future Farm Inc., we were hired for a period of 30 days to publicly disseminate information about (FFRMF) including on the Website and other media including Facebook and Twitter. We are being paid $37,500 (CASH) for and were paid 1 million shares of restricted common shares. We may buy or sell additional shares of (FFRMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 854

Lexaria Introduces TurboCBD(TM) Brand of High Absorption Full Spectrum Hemp Oil Capsules

Lexaria Bioscience Corp (LXRP)(CSE:LXX) (LXX.CN) (CNSX:LXX) (the “Company” or “Lexaria”) announces the introduction of the TurboCBD™ brand of technologically enhanced, high absorption full spectrum hemp oil capsules. Lexaria’s TurboCBD™ capsules are specially formulated with the finest American Ginseng and Ginkgo Biloba for support of enhanced focus and memory, and reduced stress and fatigue.

TurboCBD™ capsules utilize Lexaria’s patented absorption technology and are triple tested for purity. They are made without the use of organic solvents and leave no hemp oil aftertaste. They are vegan, gluten-free, sugar-free, nut-free and made in the USA. They will soon be offered for sale through California medical cannabis dispensaries and other select locations as the perfect complement to any cannabis regimen.

Lexaria’s TurboCBD™ capsules are designed to work with the physiology of the human gastrointestinal system where minute quantities of long chain fatty acids like sunflower oil, combined in each serving of TurboCBD™ capsules, are thoroughly and quickly absorbed into the circulatory system for maximum effectiveness. In vitro and human focus study testing has shown increases in CBD absorption using Lexaria’s technology by as much as 5-10 times more than conventional preparations. Those studies also demonstrated rapid onset of action in as little as 15 minutes.

Lexaria intends to showcase its TurboCBD™ capsules at the upcoming 2017 World Medical Marijuana Business Conference & Expo in Pittsburgh on April 21 and 22, which is expected to attract over 8,000 cannabis professionals including 1,200 physicians interested in the sector.

Lexaria is further researching other capsule formulations utilizing its patented absorption technology, each of which would be uniquely formulated to address specific market demands. Testing with Lexaria’s technology has shown equally good improvements in enhancing absorption and rapidity of action when working with THC as shown for CBD, and Lexaria continues to develop and seek opportunities to lever its technology for THC product applications through licensees in the USA, Canada and internationally.

About Lexaria

Lexaria Bioscience Corp is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.



This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that Lexaria’s TurboCBD™ capsules, specially formulated with the finest American Ginseng and Ginkgo Biloba, will provide any support of enhanced focus and memory or reduced stress and fatigue. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements